113MO NATALEE update: Safety and treatment (tx) duration of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC)
作者
Carlos H. Barrios,Nadia Harbeck,Gabriel N. Hortobágyi,Joyce O’Shaughnessy,Chiun‐Sheng Huang,M. Martín Jiménez,Dejan Juric,Barbara Pistilli,B. Xu,Michelino De Laurentiis,Michael Untch,Karen Afenjar,Eva Sum,Zhouxiao Li,N. Bolotova,W. Chiang,Hope S. Rugo
出处
期刊:ESMO open [Elsevier BV] 日期:2024-05-01卷期号:9: 103101-103101被引量:6
In NATALEE, RIB + NSAI showed a significant invasive disease-free survival (iDFS) benefit (HR, 0.749; 95% CI, 0.628-0.892; 1-sided P=.0006) vs NSAI alone in men and pre-/postmenopausal women with HR+/HER2− EBC. Understanding RIB tolerability is key for clinical decision making. We report RIB safety and tx duration in NATALEE.